Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct

Oncoimmunology. 2022 Jan 2;11(1):2012961. doi: 10.1080/2162402X.2021.2012961. eCollection 2022.

Abstract

Tumor-specific T cells likely underpin effective immune checkpoint-blockade therapies. Yet, most studies focus on Treg cells and CD8+ tumor-infiltrating lymphocytes (TILs). Here, we study CD4+ TILs in human lung and colorectal cancers and observe that non-Treg CD4+ TILs average more than 70% of total CD4+ TILs in both cancer types. Leveraging high dimensional analyses including mass cytometry, we reveal that CD4+ TILs are phenotypically heterogeneous, within each tumor and across patients. Consistently, we find different subsets of CD4+ TILs showing characteristics of effectors, tissue resident memory (Trm) or exhausted cells (expressing PD-1, CTLA-4 and CD39). In both cancer types, the frequencies of CD39- non-Treg CD4+ TILs strongly correlate with frequencies of CD39- CD8+ TILs, which we and others have previously shown to be enriched for cells specific for cancer-unrelated antigens (bystanders). Ex-vivo, we demonstrate that CD39- CD4+ TILs can be specific for cancer-unrelated antigens, such as HCMV epitopes. Overall, our findings highlight that CD4+ TILs can also recognize cancer-unrelated antigens and suggest measuring CD39 expression as a straightforward way to quantify or isolate bystander CD4+ T cells.

Keywords: CD39; CD4; CD8; HCMV; TIL; bystander; cancer; infiltrating; tumor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes*
  • Humans
  • Lung Neoplasms*
  • Lymphocytes, Tumor-Infiltrating / pathology
  • T-Lymphocytes, Regulatory

Grants and funding

This work was supported by the Fred Hutchinson Cancer Research Center [New Development funding]; The Andy Hill Endowment Distinguished Researcher CARE fund to E.W.N. [NA].